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Abstract
Background: The extent to which a genomic test will be used in practice is affected by factors such as ability of
the test to correctly predict response to treatment (i.e. sensitivity and specificity of the test), invasiveness of the
testing procedure, test cost, and the probability and severity of side effects associated with treatment.
Methods: Using discrete choice experimentation (DCE), we elicited preferences of the public (Sample 1, N=533 and
Sample 2, N=525) and cancer patients (Sample 3, N=38) for different attributes of a hypothetical genomic test for
guiding cancer treatment. Samples 1 and 3 considered the test/treatment in the context of an aggressive curable
cancer (scenario A) while the scenario for sample 2 was based on a non-aggressive incurable cancer (scenario B).
Results: In aggressive curable cancer (scenario A), everything else being equal, the odds ratio (OR) of choosing a test with
95% sensitivity was 1.41 (versus a test with 50% sensitivity) and willingness to pay (WTP) was $1331, on average, for this
amount of improvement in test sensitivity. In this scenario, the OR of choosing a test with 95% specificity was 1.24 times that
of a test with 50% specificity (WTP=$827). In non-aggressive incurable cancer (scenario B), the OR of choosing a test with
95% sensitivity was 1.65 (WTP= $1344), and the OR of choosing a test with 95% specificity was 1.50 (WTP= $1080). Reducing
severity of treatment side effects from severe to mild was associated with large ORs in both scenarios (OR= 2.10 and 2.24 in
scenario A and B, respectively). In contrast, patients had a very large preference for 95% sensitivity of the test (OR= 5.23).
Conclusion: The type and prognosis of cancer affected preferences for genomically-guided treatment. In aggressive curable
cancer, individuals emphasized more on the sensitivity rather than the specificity of the test. In contrast, for a non-aggressive
incurable cancer, individuals put similar emphasis on sensitivity and specificity of the test. While the public expressed strong
preference toward lowering severity of side effects, improving sensitivity of the test had by far the largest influence on
patients’ decision to use genomic testing.
Keywords: Pharmacogenomics, Genomic medicine, Personalized medicine, Genetic testing, Discrete choice experiment,
Conjoint analysis, Preference elicitation, Cancer treatment
Background
Treatment options for cancer are mainly chosen based
on the classification of the tumor and are usually based
on the best knowledge of histogenesis, histological type,
and stage of disease [1]. However, these criteria often fail
to accurately differentiate among distinct subtypes of
tumors, especially with respect to likelihood of response
to treatment, forcing clinicians and patients to choose
empirically. Thus, many patients end up experiencing
significant side effects of chemotherapy without receiv-
ing clinical benefit [2].
Recent advances in genomics have created hope that
genomic testing may help to identify patients who will
likely respond to a particular drug and/or experience
side effects. This information is valuable both for pa-
tients and physicians when choosing among possible
treatment options and trading off between risks and
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treatment of colon cancer, was initially shown to be ef-
fective only in 10% of cases. However, genomic testing
revealed that response rates were much higher in those
without a KRAS mutation in their tumor [3]. Other ex-
amples are HER2 expression in breast cancer patients,
which predicts response to trastuzumab [4] and the
BCR-ABL genotype in chronic myeloid leukemia, which
predicts response to imatinib mesylate [5].
Despite some clear advantages for the use of genomic
tests to predict response to therapy, there are also some
limitations. Genomic test results often have a probabilistic
relationship with drug response – a certain genotype in
the tumor may increase (or decrease) the probability of
treatment response but this relationship is rarely absolute
[3]. This prediction error in genomic testing may lead to
the misclassification of those that will respond (i.e. sensi-
tivity and specificity of tests are not perfect). In practice,
the extent that an imperfect genomic test will be used is
affected by multiple factors. Patients and physicians con-
sider various factors such as invasiveness of the testing
procedure, probability and severity of associated side ef-
fects of the treatment, and the overall costs before decid-
ing about the usefulness of a genomic test [6,7].
The other important challenge is the impact of gen-
omic testing on health care costs. An increasing number
of diagnostic and predictive tests as a result of advances
in genomics are creating increasing pressure on already
soaring health care costs. There are ongoing debates
about added clinical and economic value of these new
technologies and appropriate methods for measuring
those potential benefits [8,9]. New genomic tests, even if
proven to deliver clinical benefit, are rarely cost saving.
Thus, the decision about their overall value should be
made based on the appropriate balance between clinical
benefits and the costs of these technologies. In this con-
text, it is important to determine which attributes of a
genomic test are of more importance for patients when
deciding about their treatment options. In general, ap-
proval and use of genomic tests varies widely across dif-
ferent jurisdictions and for different populations.
Publicly (or privately) funded health care benefit pro-
viders are often interested in learning about tax payers’
(or privately insured populations’) opinion about the
value of these genomic tests. Knowledge about these
preferences will enable health benefit providers to select
genomic tests with the highest perceived value when
making funding decisions. This information can be used
to prioritize future research areas and suggest aspects of
genomic testing where improvement will have the most
value to patients. Finally, this investigation may offer fur-
ther insight about perceptions of patients who have dir-
ectly experienced the disease and about their evaluation
of different aspects of testing for cancer treatment. This
information can potentially help physicians to offer
treatment options that better match patients values and
preferences [10].
Using a discrete choice experiment (DCE), we explored
the relative impacts (i.e. relative preference weights) of dif-
ferent attributes of a genomic test on individuals’ decision
to use the test for guiding cancer treatment. We investi-
gated whether these relative impacts are influenced by
type of cancer and its prognosis. Finally, we investigated
how these relative impacts may differ between cancer pa-
tients and the public. Our knowledge about these relative
preference weights can offer a value-based framework [11]
for evaluating and comparing new genomic tests.
Methods
Study sample
Two samples from the public (sample 1 and sample 2)
and a sample of current or former cancer patients partici-
pated in this study. The samples from the public (sample
1 and sample 2) were recruited by Ipsos Reid (Vancouver,
British Columbia) and were representative of the Canadian
general population in terms of demographics and socio-
economic characteristics. The third sample (sample 3)
consisted of current or former lymphoma patients who
had voluntarily agreed be contacted about research pro-
jects in British Columbia (BC), Canada.
All subjects were invited to participate in this web-
based study through email. All participants were at least
19 years old and were able to read and write in English.
In the initial letter, we provided a brief description of the
study and invited individuals to participate. Once they
agreed, each participant provided informed consent and
then followed a web link to the online questionnaire.
Participants could choose not to answer any of the ques-
tions or withdraw at any point. The protocol for this
study was reviewed and approved by the University of
British Columbia - British Columbia Cancer Agency
(BCCA) Research Ethics Board.
Study procedure
At the beginning of the DCE questionnaire, we de-
scribed one of two possible scenarios to the participants.
We asked participants to imagine a situation where they
have been diagnosed with either an aggressive curable
cancer (scenario A) or a non-aggressive incurable cancer
(scenario B) and that they have the option to choose a
genomic test that can predict the likelihood of their re-
sponse to a new chemotherapy (Table 1). We explained
that the genomic test had limited accuracy, which might
result in false negative (misclassifying responders as
non-responders) and false positive (misclassifying non-
responders as responders) predictions. Finally, we ex-
plained the attributes and levels in the DCE questionnaire
(Table 2) and asked participants to complete 16 choice
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three samples, but varied the underlying form of cancer
described for one of the samples from the public: the
preamble in the questionnaire described an aggressive
curable cancer (scenario A) to participants in the first
sample from the public and the sample from patients,
and a non-aggressive, incurable cancer (scenario B) as
the scenario for the second sample from the public. The
design of the DCE questionnaire has been explained in
the next section and a sample choice task has been pre-
sented in Table 3.
The extent to which a genomic test will be used in prac-
tice is affected by the perceived benefits, risks and costs of
using the genomic test. As such, in the DCE questionnaire
participants needed to make a trade-off between the con-
sequences of not taking the new chemotherapy when in
fact it was beneficial, experiencing additional side effects
of new chemotherapy without receiving any clinical
Table 1 Scenarios for DCE
Scenario A: Scenario B:
Aggressive curable Cancer Non-aggressive incurable Cancer
Imagine that you have recently been diagnosed with a fast-acting but
curable form of cancer. Currently, approximately 50 out of 100 (50%) of
patients are cured after the first round of chemotherapy. If you are cured
by this initial treatment, you will have a normal life expectancy; otherwise
your life expectancy is approximately 1 year. In this case you will be given
the second round of chemotherapy but your chance of being cured is
about 10 out of 100 (10%).
Imagine that you have recently been diagnosed with a slow-acting but
incurable form of cancer. This means that the spread of the disease is
usually slow, but treatments are only able to slow the spread further, and
cannot cure the disease. Your life expectancy after being diagnosed with
this type of cancer is approximately 10 to 13 years. You will receive treat-
ment after you start experiencing symptoms, which may take several
years after your initial diagnosis. Even if your treatment is successful, you
are likely to experience numerous relapses, in which the disease returns
after a period of improvement. These relapses will be treated until all
options for treatment have been exhausted.
By adding a new medication to the first round of chemotherapy the cure
rate increases from 50 out of 100 (50%) to 75 out of 100 (75%) . However,
only some of individuals can benefit from the new medication
(responders) and other individuals receive absolutely no benefit from
adding the new medication to the standard chemotherapy
(non-responders).
By adding a new medication to the first round of chemotherapy your life
expectancy can be increased by 2 years on average. However, only some
of individuals can benefit from the new medication (responders) and
other individuals receive absolutely no benefit from adding the new
medication to the standard chemotherapy (non-responders).
The downside of adding the new medication to the standard
chemotherapy is that it increases the likelihood and severity of treatment
side-effects.
The downside of adding the new medication to the standard
chemotherapy is that it increases the likelihood and severity of treatment
side-effects.
Table 2 Attribute and levels included in the DCE questionnaire
Attribute Levels
Untreated responders
&: 5%, 20%, 35%, 50%
Proportion of patients who could be cured by the new medication (responders) but will not receive it
as a result of inaccurate genetic test result.
Unnecessary treatment of non-responders
†: 5%, 20%, 35%, 50%
Proportion of patients who would not benefit from the new medication (non-responders) but will receive
it as a result of wrong genetic test result.
Severity of side effects: Severe, Moderate, Mild
The new medication may be associated with side effects such as nausea, hair loss, skin rash and fatigue.
The potential levels of Side Effect Severity were:
Likelihood of side effects: 5%, 50%, 95%
The side effects described in Attribute 3 will not necessarily occur for all individuals. Instead, they will
occur with a particular percentage chance. Possible levels were:
Genetic test turnaround time: 2 days, 7 days, 12 days
The time required to obtain the genetic test results, after the test has been performed.
Genetic test procedure: Mouth swab, Blood sample,
Tumor biopsy, Bone marrow
biopsy, Liver biopsy Type of the procedure that is needed for doing the genetic test.
Genetic test cost: $50, $500, $1000, $1500
Please assume that you would be paying only for the genetic test out-of-pocket.
&1-Sensitivity.
†1-specificity.
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the test turnaround time, and the cost of the genomic test.
The descriptions at the beginning of the questionnaire
explicitly stated that in the absence of a genomic test, all
patients would be offered the new chemotherapy. As such,
choosing the “neither” option in a choice task implied a
respondent’s preference for opting-out from genomic test-
ing and taking the new chemotherapy regardless of the
likelihood of response. We did not specify the type of can-
cer, treatment, and the associated genomic test to increase
the generalizability of the results. Nonetheless, the sample
of patients in this study were former and current lymph-
oma patients in British Columbia, and the disease descrip-
tions provided in the DCE questionnaires were similar to
aggressive and non-aggressive types of lymphoma.
Questionnaire design
Discrete choice experiment is a method to elicit individ-
uals’ strength of preferences for different aspects of a
health intervention (or a product in general). The concept
of DCE is based on Random Utility Theory and the as-
sumptions that: 1) a health care intervention (or any prod-
uct or service in general) can be characterized by several
attributes; and 2) individuals choose among available
health interventions (or products or services) by evaluat-
ing and comparing their attributes [12-14]. These attri-
butes can describe health outcomes (e.g. test accuracy,
likelihood or severity of treatment side effects) or inter-
vention process (cost, test procedure, or turnaround time).
In this study, we assumed that a genomically-guided
cancer treatment could be described by seven attributes
(Table 2). Considering that a large number of (hypothet-
ical) treatment options can be generated by using these
attributes and all various combinations of their levels
(i.e. full factorial design), we implemented a fractional
factorial design where we selected 10 versions of the
DCE questionnaire each consisting of only 16 choice
tasks. Therefore, each respondent had to complete a
randomly assigned version of the DCE questionnaire
that contained 16 choice tasks. In each choice task,
respondents had to choose between two treatment op-
tions and a neither option. A sample choice task has
been presented in Table 3 and the complete DCE ques-
tionnaire can be found in Additional file 1. The effi-
ciency of our fractional factorial design was assured
using simulation of responses. We generated large num-
ber of possible designs and then selected the design that
provided the most precise coefficient estimates (i.e.
smallest standard errors) and a better D-efficiency given
the sample size [14,15]. The statistical design of the
questionnaire ensured that a random selection of re-
sponses would result in preference weights that are not
statistically different from zero (i.e. non-informative co-
efficient estimates).
Several sources were used for selection of attributes
including published literature, physicians’ opinion, and
feedbacks that we received from three pilot surveys. We
identified several studies that had investigated character-
istics of pharmacogenomic testing and their impact on
patients’ and physicians’ decisions for utilizing them
[16-18]. We compiled a list of attributes based on the re-
sults of these studies and discussed this list with physi-
cians who were in direct contact with cancer patients in
the BC cancer agency. We then selected the seven attri-
butes deemed to have the greatest influence on patient’s
decisions about treatment options. These attributes and
levels were then tested in a pilot study where 7 former
cancer patients and 50 individuals from the public com-
pleted the preliminary version of the DCE questionnaire.
By analyzing the data in the pilot phase, we examined
rationality and consistency of the responses and whether
the estimated coefficients conformed to our prior ex-
pectation in terms of direction and sign. Our prior ex-
pectation was based on the assumption that individuals’
preferences (and willingness to pay) decrease by decreas-
ing sensitivity and specificity of the test, and by increas-
ing severity and likelihood of side effects, turnaround
time, cost, or invasiveness of the testing procedure.
Using this approach, we ensured that the respondents
understood the content of the DCE questionnaire and
our instructions for completion of choice tasks. Further-
more, we used the comments provided by respondents
at the end of the questionnaires to hone the preamble,
descriptions, attributes, and levels used in the final ver-
sion of the questionnaire.
Two out of 16 choice tasks in the DCE questionnaire
contained a clearly dominant option. By checking answers
to these fixed choice tasks, we tested if respondents actu-
ally read and understood the DCE questionnaire. These
fixed choice tasks are usually part of the DCE question-
naire design in order to verify consistency and rationality
of responses. We also included the “neither” option in the
choice tasks to provide the possibility to opt-out whenever
none of the presented alternatives was adequately
Table 3 A sample choice task
Attributes Option 1 Option 2 Neither
Untreated responders 50 out of 100 5 out of 100 0 out of 100
Unnecessary treatment
of non-responders
50 out of 100 5 out of 100 100 out of 100
Severity of side effects Moderate Mild Severe
Likelihood of side effects 50 out of 100 5 out of 100 95 out of 100
Cost of genetic test $1000 $500 $0
Genetic test turnaround
time
7 days 2 days 0 days
Genetic test procedure Bone Marrow Biopsy Blood Sample None
Which option you
would choose?
OO O
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demanders to choose an alternative and ensured estimation
of unconditional rather than conditional preferences [14].
The design of the web-based questionnaire, which facili-
tated direct data entry into our secured server, was done
using the Choice Based Conjoint (CBC) application of
Sawtooth (Sawtooth software Inc, SSI web version 6.6.6).
Statistical analysis
Assuming the general framework used in random utility
theory [14], given a set of options, the log odds ratio of
choosing one of the options is proportional to a linear
function of attributes of that option. Therefore, by gath-
ering stated choice data using a DCE questionnaire with
a known statistical design and by knowing attributes and
levels presented in each choice task, the coefficients of
attributes can be estimated using generalized linear
models. These coefficients, also known as relative prefer-
ence weights, reflect average impact of attribute levels
on likelihood of being chosen as the preferred option.
Also the ratio of coefficients can be interpreted as mar-
ginal rate of substitution (MRS) between any two attri-
butes. By inclusion of cost as an attribute in the DCE
questionnaire, the marginal rates of substitution between
each attribute and cost, also known as Willingness to
Pay (WTP) [14], can be calculated. WTP can provide
useful interpretations for estimated preference weights
as they indicate how much individuals on average are
willing to pay to receive a certain amount of change in one
of the attribute levels [14]. The odds ratios (OR) as-
sociated with each attribute levels also were calcu-
lated. These odds ratios suggest, given two options
w i t ht h es a m ea t t r i b u t el e v e l s ,h o wac h a n g ei no n e
of the attribute levels will affect the odds of becom-
ing the preferred choice.
The choice data were effect-coded for attributes with
discrete values, with the exception of cost, which was
modeled as a continuous variable [19]. Effect coding of
choice data, instead of continuous coding, relaxes linear-
ity assumptions and allows detecting non-linearity of
preference weights in regards to different levels of an at-
tribute. Also modeling cost as a continuous variable
allowed us to estimate WTP values in a way that is easy
to interpret. An alternative specific variable was dummy
coded and indicated the situations where “neither” was
chosen [14,20]. The choice data was analyzed using
PROC MDC, SAS 9.2. We pooled the choice data from
two samples from the public who completed the ques-
tionnaire under scenario A and scenario B and estimated
a conditional logit model using choice as the dependent
variable. We defined a dummy variable that indicated
the scenario in the pooled data. By including interaction
terms between this dummy variable and attribute levels
in the regression analysis, we compared the estimated
preference weights across two samples from the public.
We also used the same approach to compare estimated
preference weights in the samples from the public and
patients who had both completed the questionnaire
under scenario A. However, prior to doing this analysis,
we used the propensity score method to select a sub-
sample of the public that were similar to the sample of
patients in terms of age, education, income, and having
dependent children. Considering that the characteristics
of patients in our sample were different from the public,
using propensity scores was necessary to increase com-
parability of the results across the samples from the pub-
lic and patients in our analysis.
There are a variety of statistical methods for the ana-
lyses of DCE data that range from conditional logit
models to Bayesian mixed logit models [21] and Latent
Class Analysis (LCA) [22]. Critical assessment of these
methods can be found elsewhere [23]. We chose condi-
tional logit model for analyses of the DCE data in this
study. However, we verified the estimated results and ro-
bustness of our findings by re-running the regressions
using a mixed logit model.
Results
Sample characteristics
Invitations were initially sent to 904 and 836 individuals
from the public for participation in the study under sce-
narios A and B, respectively. Although 588 (65%) indi-
viduals in scenario A and 578 (69%) individuals in
scenario B provided their responses to the question-
naires, some of the questionnaires contained uncom-
pleted choice tasks. To avoid potential bias as a result of
imbalanced frequency of responses, we decided to re-
strict our analysis to the data from questionnaires with
complete responses to all choice tasks (533 individuals
in scenario A and 525 individuals in scenario B). Our
sample of patients was limited to an email list provided
by BC cancer Agency (BCCA). We initially contacted a
list of 84 patients through email and 54 (64%) patients
agreed to participate in this study. However, after ex-
cluding incomplete responses, we had choice data from
38 patients for the final analysis.
Table 4 has summarized the characteristics of the par-
ticipants in the three samples. Mean age in the sample
of patients was 58.2 years, about 10 years higher than in
the samples from the public. Also 36.1% of individuals in
the sample from patients reported a household income
of ≥ Can $125,000 (This rate was 6.6% and 5.5% in the
samples from the public). Patients who participated in
this study were also highly educated and 32.4% had a
master or doctorate degree (the proportions of individ-
uals with master or doctorate degree were 2.5% and
4.1% in the samples from the public under scenario A
and scenario B, respectively).
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Comparing preferences of the public under two scenarios A
and B
The estimated preference weights, odds ratios, and the
WTP associated with the levels in each attribute have
been reported in Table 5.
The results suggested that in aggressive curable cancer
(scenario A), the preference weight of the public for
“sensitivity: 50%” was −0.1686 (s.e. 0.466) and it in-
creased to 0.1748 (s.e. 0.0266) for a test with “sensitivity:
95%” (Table 5). Alternatively, the impact of test sensitiv-
ity on respondent’s choice is evident in the reported ORs
and WTPs. For example, everything else being equal, the
odds of choosing a test with 95% sensitivity were 1.41
times the odds of choosing a test with 50% sensitivity
and they were willing to pay $1331 for increasing test
sensitivity from 50% to 95%. However, they were willing
to pay only $796 and $487 for increasing sensitivity to
80% and 65%, respectively. In non-aggressive incurable
cancer (scenario B), preference weights of “sensitivity:
95%” and “sensitivity: 50%” were 0.2577 (s.e. 0.270) and
−0.2436 (s.e. 0.0479), respectively. Increasing sensitivity
from 50% to 95% increased the odds of choice by 1.65
times. Although this preference weight in scenario B was
larger compared to scenario A (0.2577 vs. 0.1748, differ-
ence p-value =0.0241), corresponding willingness to pay
values were comparable ($1331 vs. $1344 in scenario B
and A, respectively). Preference weights and WTPs for a
test with sensitivity of 80% or 65% in scenario B were
not significantly different from corresponding values in
scenario A.
In scenario A, the odds of choosing a test with 95% spe-
cificity were 1.24 times the odds of choosing a test with
50% specificity and the public was willing to pay $827 for
this amount of improvement in specificity level. The pref-
erence weight for 95% specificity was more than two-fold
larger under scenario B compared to scenario A (0.2452,
0.1008, difference p-value<0.001). Therefore, under sce-
nario B, the odds of choosing a test with 95% specificity
were 1.50 times the odds of choosing a test with 50% spe-
cificity and the corresponding WTP was $1080. Also in
scenario B, the preference weight of 65% specificity was
negative (−0.1251) and statistically different (difference
p-value=0.0115) from its counterpart under scenario A
(0.0051). The public perceived little value in increasing
specificity from 50% to 65% in scenario B.
Reducing severity of treatment side effects from severe
to mild was associated with large ORs in both scenarios
(OR=2.10 and 2.24 in scenario A and B, respectively).
The public was willing to pay as much as $2882 and
$2165 to receive a treatment with mild rather than severe
side effects in aggressive curable cancer (scenario A) and
non-aggressive incurable cancer (scenario B), respectively.
Furthermore, the odds of choosing a treatment with 5%
likelihood of side effects were 1.62 and 1.75 times the odds
of choosing a treatment with 95% likelihood of side effects
in scenario A and B, respectively.
Shortening test turnaround time from 12 days to ei-
ther 7 days or 2 days had the smallest impact on prefer-
ence weights, ORs, and WTPs under both scenarios. In
contrast, the level of invasiveness of the testing proced-
ure had a large impact on estimated preference weights,
Table 4 Characteristics of participants
The public,
scenario A
The public,
scenario B
Patients,
scenario A
N= 533 N =525 N = 38
Age (years) N= 512 N =510 N = 37
Mean (std) 48.2 (15.7) 47.6 (15.9) 58.2 (9.4)
Education (%) N= 529 N =514 N = 37
Some high school 6.8% 6.6% 0%
High school 42.2% 45.5% 2.7%
College 36.1% 35.4% 27.0%
Bachelor degree 12.5% 8.4% 37.8%
Master degree 1.9% 3.5% 27.0%
Doctorate 0.6% 0.6% 5.4%
Gender N= 522 N =516 N = 36
Female 48.5% 50.6% 58.3%
Male 51.5% 49.4% 41.7%
Number of dependent children N= 532 N =517 N = 36
None 57.9% 56.5% 69.4%
1 14.3% 15.5% 5.6%
2 16.2% 16.1% 13.9%
3 or more 11.6% 12.0% 11.1%
Description of current health
situation
N= 526 N =521 N = 37
Excellent 8.9% 11.3% 10.8%
Very good 29.9% 28.6% 16.2%
Good 29.1% 33.6% 32.4%
With some health problems 28.7% 23.8% 21.6%
Having serious health
problems
3.4% 2.7% 18.9%
If knew anyone diagnosed with
cancer
N= 528 N =519 N = 36
Yes, very closely 17.8% 16.2% 2.8%
Yes 38.1% 41.6% 30.6%
No 44.1% 42.2% 66.7%
Household’s annual income (Can$) N = 516 N = 509 N = 36
Less than 25000 15.5% 13.2% 2.8%
25000 to 50000 30.2% 35.6% 27.8%
50000 to 75000 23.1% 23.6% 11.1%
75000 to 100000 16.9% 12.6% 13.9%
100000 to 125000 7.8% 9.6% 8.3%
More than 125000 6.6% 5.5% 36.1%
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the public was willing to pay $2162 and $1474 for a gen-
omic test that could be performed using a mouth swab
rather than one involving a liver biopsy in scenario A
and B, respectively.
Individuals from the public had negative preference
weights for opting out from genetic testing (i.e. choosing
“neither” option). The preference weight was a larger
negative number under scenario A compared to scenario
B( −0.6323 in scenario A vs. -0.4967 in scenario B,
Table 5 Estimated preference weights and Willingness to Pay (WTP) in samples from the public
The public,
scenario A
(N=533) The public,
scenario B
(N=525) P-value for
difference
Coefficient (s.e.) OR MWTP Coefficient (s.e.) OR MWTP
Untreated responders
&
5% 0.1748 (0.0266)** 1.41 1,331 0.2577 (0.0270)** 1.65 1,344 0.0241
20% 0.0367 (0.0265) 1.23 796 0.0324 (0.0274) 1.32 740 0.8487
35% −0.0429 (0.0276) 1.13 487 −0.0465 (0.0285) 1.22 528 0.9315
50% −0.1686 (0.0466) 1 Ref −0.2436 (0.0479)** 1 Ref
Unnecessary treatment of non-responders
†
5% 0.1008 (0.0268)** 1.24 827 0.2452 (0.0270)** 1.50 1,080 0.0004
20% 0.0065 (0.0274) 1.13 461 0.0377 (0.0288) 1.22 524 0.6691
35% 0.0051 (0.0272) 1.12 456 −0.1251 (0.0281)** 1.03 88 0.0115
50% −0.1124 (0.0470) 1 Ref −0.1578 (0.0485)** 1 Ref
Severity of side effects
Mild 0.3319 (0.0205)** 2.10 2,882 0.3295 (0.0211)** 2.24 2,165 0.3838
Moderate 0.0798 (0.0210)** 1.63 1,905 0.1484 (0.0217)** 1.87 1,679 0.0621
Severe −0.4117 (0.0293)** 1 Ref −0.4779 (0.0303)** 1 Ref
Likelihood of side effects
5% 0.2490 (0.0204)** 1.62 1,861 0.2622 (0.0213)** 1.75 1,497 0.2245
50% −0.0179 (0.0209) 1.24 826 0.0340 (0.0214) 1.39 885 0.2261
95% −0.2311 (0.0292)** 1 Ref −0.2962 (0.0302)** 1 Ref
Genetic test turnaround time
2 days 0.1213 (0.0210)** 1.26 911 0.1266 (0.213)** 1.27 650 0.4533
7 days −0.0076 (0.0208) 1.11 411 −0.0107 (0.0218) 1.11 282 0.5396
12 days −0.1137 (0.0296)** 1 Ref −0.1159 (0.0305)** 1 Ref
Genetic test procedure
Mouth swab 0.2962 (0.0304)** 1.75 2,162 0.3045 (0.0311)** 1.73 1,474 0.9942
Blood sample 0.2863 (0.0320)** 1.73 2,124 0.3882 (0.0332)** 1.88 1,698 0.5738
Tumor biopsy −0.0416 (0.0326) 1.25 853 −0.0809 (0.0332)** 1.18 440 0.8152
Bone marrow biopsy −0.2792 (0.0321)** 0.98 −68 −0.3666 (0.0339)** 0.89 −325 0.6879
Liver biopsy −0.2617 (0.0636)** 1 Ref −0.2452 (0.0675)** 1 Ref
Neither (No test) −0.6323 (0.0379)** 0.53 −2,451 −0.4967 (0.0389)** 0.61 −1,332 0.0169
Genetic test cost −0.00026 (0.00003)** Ref −0.00037 (0.00003)** Ref 0.0091
McFadden’s LRI 0.17
Adjusted Estrella 0.33
Log-likelihood Ratio 6216.5
AIC 31050
Schwartz Criterion 31329
** p-value < 0.01.
&1-Sensitivity.
†1-specificity.
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http://www.biomedcentral.com/1472-6963/13/454difference p-value=0.0169). The ORs of opting-out from
genetic testing (vs. taking a test) were 0.53 and 0.61 in
scenario A and B, respectively. The public had a larger
WTP for having a test in aggressive curable cancer sce-
nario ($2451) compared with non-aggressive incurable
cancer ($1332). Finally, the preference weight for “gen-
etic test cost” was a larger negative number under sce-
nario B compared to scenario A (−0.00026 in A vs.
-0.00037 in B, difference p-value =0.0091), indicating
that the public was more sensitive to price in scenario B.
Comparing preferences of the public with preferences of
patients under scenario A
Using propensity scoring we identified a subsample of
the public (N =83) who had similar characteristics to pa-
tients (N =38) in terms of age, education, income, and
number of dependent children. Next we pooled the data
from two samples (N =121) and fitted a conditional logit
model to estimate preference weights, ORs, and WTPs
associated with each attribute levels (Table 6).
The preference weight of patients for “sensitivity: 95%”
was significantly larger compared to the public (0.2480
in the public vs. 0.8794 in patients, difference p-value <
0.001). This large difference in preference weights for
“sensitivity: 95%” also translated into large differences in
WTP estimates ($2,658 for the public vs. $12,820 for pa-
tients) and ORs (1.53 vs. 5.23, respectively). Patients’ had
consistently larger preference weight for better sensitiv-
ity and specificity of the test, as was evident based on
ORs and WTP values associated with different levels of
sensitivity. Among patients, the odds of choosing a genetic
test that requires “mouth swab” were 2.43 times the odds
of a test that needs liver biopsy. Patients also preferred a
test that involves “Bone marrow biopsy” instead of “liver
biopsy” (OR=1.76), while the public considered both types
of biopsies equally unfavorable (OR=1.04). There was a
large difference between preference weight of the public
versus patients for opting-out from the test (−1.0346 in the
public vs. -0.1185 in patients, difference p-value= 0.0002).
Consequently, the public was willing to pay as high as
$6050 for having a genetic test while patients’ WTP for
genetic testing was only $919. This indicated patients had
significantly less aversion to opting out of genomic testing.
Discussion
This study shows the relative impact of different proper-
ties of genomically-guided cancer treatment on test up-
take. Change in severity and likelihood of side effects as
well as the test procedure have the largest influence on
the public’s decision to use genetic testing. In contrast,
improving sensitivity of the test had a larger influence
on patients’ decision to use genomic testing.
The type of cancer and its prognosis also influenced
the preferences of the public for different attributes of
genomic testing. When we compared the results in the
two samples from the public, we found that in aggressive
curable cancer, individuals emphasized the sensitivity ra-
ther than specificity of the test. In contrast, for a non-
aggressive incurable cancer, individuals put similar em-
phasis on the sensitivity and specificity of the test and
expressed strong (positive and negative) preferences to-
ward (high and low) specificity of the test. Furthermore,
under this scenario (non-aggressive incurable cancer)
the public also had a larger negative preference toward
the cost of genomic testing. Because for a non-
aggressive incurable cancer the change in the survival is
ultimately small and is expected to be materialized after
13 years, this lead to the public discounting the benefits
of new chemotherapy and becoming more selective
about accuracy of genomic testing in this scenario.
Our study suggests that patients and the public have
different perceptions about the value of various aspects
of genomic testing to guide cancer treatment when fa-
cing an aggressive curable cancer. Based on our results,
patients were mostly concerned about improving sensi-
tivity of the test (and presumably their survival chance),
and in the absence of an adequately sensitive test they
preferred opting-out from genomic testing and taking
the treatment regardless of its side effects. Conversely,
the public had a large negative preference weight for
opting-out from genomic testing suggesting that they
are more inclined to use a test even with inadequate ac-
curacy. This information may help physicians to tailor
their clinical advice considering type of cancer and pre-
vious experience of their patient with cancer treatment.
For example, if the prognosis of disease is expected to
be similar to our scenario for non-aggressive incurable
cancer, then perhaps discussing false positive rates of
available tests can be of great importance for the average
patient. Also, the observed differences between prefer-
ences of patients and the public about different biopsy
procedures suggest that perhaps physicians can help pa-
tients who have no prior experience of cancer treatment
in developing a more realistic perception about the rela-
tive invasiveness of these procedures.
There is a paucity of studies about preferences for
characteristics of genomic testing. The increasing num-
ber of new genomic tests ensuing from fast develop-
ments in genomic sciences underlines the need for
further investigations in this area. Knowledge about
strength of preferences toward different attributes of
genomic testing can lead us toward value-based evalu-
ation of these new technologies. In health care systems
that rely on public funding resources, by considering
these preference weights in funding decisions, genomic
tests with potentially higher value for a covered popula-
tion can be determined. In addition, physicians can have
better understanding about patients’ priorities given the
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preferences of patients and the public shown in our
study also suggests areas that physicians should
emphasize when communicating with recently diag-
nosed patients who presumably have no prior experience
of the disease. In a study conducted by Griffith et al.,
willingness to pay for receiving breast cancer genomic
services was estimated by conducting a DCE on 242 in-
dividuals with high, moderate, and low risk of develop-
ing breast cancer [24]. Using a DCE and following a
Table 6 Estimated preference weights and Willingness to Pay (WTP) in a propensity score matched subset of the public
and patients
The public, scenario A (N=83) patients, scenario A (N= 38) P-value for
difference
Coefficient (s.e.) OR MWTP Coefficient (s.e.) OR MWTP
Untreated responders
&
5% 0.248 (0.0687)** 1.58 2,658 0.8794 (0.1068)** 5.23 12,820 <.0001
20% 0.0528 (0.0676) 1.30 1517 0.0442 (0.1068) 2.27 6,346 0.6084
35% −0.0942 (0.0702) 1.12 657 −0.1492 (0.1133) 1.87 4,847 0.6582
50% −0.2066 1 Ref −0.7744 1 Ref
Unnecessary treatment of non-responders
†
5% 0.1867 (0.0679)** 1.39 1,919 0.1083 (0.1083) 1.59 3,580 0.9663
20% 0.0134 (0.0697) 1.17 906 0.2391 (0.1112)* 1.81 4,594 0.1598
35% −0.0586 (0.0683) 1.09 485 0.0062 (0.1088) 1.43 2,789 0.657
50% −0.1415 1 Ref −0.3526 1 Ref
Severity of side effects
Mild 0.2712 (0.0524)** 2.10 4,327 0.3084 (0.0839)** 2.09 5,716 0.7
Moderate 0.1976 (0.053)** 1.95 3,897 0.1206 (0.0871) 1.73 4,260 0.3008
Severe −0.4688 1 Ref −0.4290 1 Ref
Likelihood of side effects
5% 0.2645 (0.0521)** 1.65 2,937 0.2735 (0.0838)* 1.60 3,650 0.8119
50% −0.0267 (0.0529) 1.24 1,235 −0.0762 (0.0864) 1.13 939 0.5678
95% −0.2378 1 Ref −0.1973 1 Ref
Genetic test turnaround time
2 days 0.1673 (0.0531)** 1.40 1,978 0.0174 (0.087) 1.15 1,117 0.2467
7 days 0.0036 (0.0521) 1.19 1,021 0.1093 (0.0857) 1.27 1,829 0.5259
12 days −0.1709 1 Ref −0.1267 1 Ref
Genetic test procedure
Mouth swab 0.2591 (0.0783)** 1.75 3,258 0.3918 (0.1239)* 2.43 6,881 0.4303
Blood sample 0.3382 (0.0825)** 1.89 3,720 0.1168 (0.1322) 1.85 4,750 0.2508
Tumor biopsy −0.04 (0.0828) 1.29 1,509 −0.0829 (0.1342) 1.51 3,202 0.7787
Bone marrow biopsy −0.2593 (0.081)** 1.04 226 0.0702 (0.1286) 1.76 4,388 0.1121
Liver biopsy −0.2980 1 Ref −0.4959 1 Ref
Neither (No test) −1.0346 (0.1037)** 0.36 −6,050 −0.1185 (0.1382) 0.89 −919 0.0002
Genetic test cost −0.00017 (0.00007)* Ref −0.00013 (0.00012) Ref 0.1901
McFadden’s LRI 0.20
Adjusted Estrella 0.35
Log-likelihood Ratio 832.8
AIC 3493
Schwartz Criterion 3694
** p-value < 0.01; * p-value < 0.05.
&1-Sensitivity.
†1-specificity.
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the factors that influenced participation in genomic car-
rier testing for Tay Sachs and cystic fibrosis among a
sample from the general community and a sample of the
Ashkenazi Jewish community. A recent study [26] also
used DCE to estimate the tradeoffs among sensitivity,
turnaround time, and cost of a postnatal genomic test to
predict genomic abnormalities causing mental retard-
ation in children. Finally, in a study done by Herbild
et al. [27], they elicited preferences in the Danish general
population for taking a pharmacogenomic test that could
improve treatment of depression.
Patients’ emphasis on sensitivity also has been shown
in the context of using usual screening tests for colorec-
tal cancer [28]. In exploring preferences of 1047 patients
with a history of colorectal cancer for different screening
modalities, Marshall et al. used a DCE and estimated
how likelihood of uptake may be affected by different
characteristics of the test. Similar to our results, they
found that sensitivity of the test has the largest impact
on the likelihood of uptake among these patients. A
cross sectional survey study by Haga et al. also showed
that primary care physicians consider the severity of side
effects followed by predictive accuracy of a phramacoge-
nomic test as the factors that have the largest influence
on their decision to prescribe it to their patients, while
turnaround times have a smaller influence on their deci-
sion for using pharmacogenomics testing [16]. These re-
sults, when considered in the context of our findings,
suggest that perhaps neither the public nor physicians
share patients’ highest priority for better test sensitivity.
Direct comparison of physicians and patients prefer-
ences about genomic testing can provide useful insight
about this matter and should be pursued further in fu-
ture research.
The distinct characteristic of our study is utilizing
three samples to demonstrate how the type of cancer
and its prognosis affected preferences for a genomic test,
and how preferences of patients differed from those of
the public. Also, in contrast with previous studies, the
results of our study are applicable to most genomic tests
for guiding cancer treatment, as we did not specify the
type of cancer, treatment, or the associated genomic test.
However, we acknowledge that in the absence of specify-
ing the type of cancer, participants may make various as-
sumptions about possible prognosis and potential
outcomes. Therefore, this can be seen as a limitation of
our study as well. Throughout this study, participants
provided their choices considering the following as-
sumptions: 1) if they decided to opt-out from genomic
testing, they would receive the new treatment regardless
of its effect, and 2) the new treatment was covered by
their insurance policies. We acknowledge that under dif-
ferent circumstances in terms of the effect of genomic
testing on access to the new treatment, the current re-
sults may not apply. The larger standard errors around
the estimated coefficients in patients suggested that this
sample was slightly underpowered. However, the sample
size was restricted to a list of lymphoma patients in BC
cancer agency’s contact list and willingness of those
approached to participate and thus could not be in-
creased. Despite this limitation, all of the point estimates
in the sample of patients were in line with our prior ex-
pectations in terms of the order of their magnitudes and
corresponding signs. Moreover, this sample was not an
archetypal sample of cancer patients in BC, as they had
high income, high education level, and were 10 years
older on average. Therefore, we used propensity scoring
to find a subsample of the public with similar character-
istics to increase comparability of the results. This issue,
however, potentially limits the external validity of the re-
sults based on these samples. Actual decisions that pa-
tients or the public make in real life situations may
deviate from their stated preference in surveys like ours.
This effect has been shown in the context of genetic
testing as well [29]. However, several studies provide evi-
dence suggesting strong correlation between stated and
real WTP [30] and preferences [31]. Answering DCE
questions can be a complex task and accuracy of re-
sponses may eventually depend on participants’ numeracy
level (i.e. ability to interpret quantitative information) [32],
language skills, familiarity of subject, and attentiveness
while completing the questionnaire. We have used sev-
eral standard approaches to assure quality of the data
by including a fixed choice task to test rationality of re-
sponses and by checking the time that each respondent
spent on completing the questionnaire. Overall, given
t h ed i r e c t i o n sa n ds i g n so ft h ee s t i m a t e dp r e f e r e n c e
weights, we believe that our results are robust and have
not been compromised by these potential problems.
Finally, we acknowledge that the factors that can affect
uptake of a genomic test are not limited to the seven
attributes that we have included in the current DCE
design. We excluded several important aspects (e.g. risk
involved in testing procedure) that individuals may take
into account when making their actual decision about
using genomic testing. This selection was to use the
minimum possible number of attributes and avoid
overly complex choice tasks [33].
Our study demonstrates individuals’ preference strength
toward characteristics of a genomic test when they are
faced with an aggressive but curable cancer versus a non-
aggressive and incurable cancer. Additionally, these results
suggest which characteristics of genomic testing have a
larger potential value for society and patients. Physicians
may find these average preferences as a benchmark
when providing treatment advice about pharmaco-
genomics testing to cancer patients. These preference
Najafzadeh et al. BMC Health Services Research 2013, 13:454 Page 10 of 12
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by incorporating relevant populations’ valuation of dif-
ferent aspects of genomic testing.
Conclusions
We explored the relative impact of different properties
of genomically-guided cancer treatment on test uptake.
We found that the type and prognosis of cancer affected
preferences for genomically-guided treatment. Our re-
sults also suggest that patients and the public have dif-
ferent perceptions about the value of various aspects of
genomic testing to guide cancer treatment. Physicians
may find these average preferences as a benchmark
when providing treatment advice about pharmacogen-
omics testing to cancer patients. These preference
weights also can be used to inform funding decisions by
considering relevant populations’ valuation of different
aspects of genomic testing.
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